Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study

References

• VinayDS, RyanEP, PawelecG, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185–S198.25818339
   PubMed Web of Science ®Google Scholar
• AyoubNM, Al-ShamiKM, YaghanRJ. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer (Dove Med Press). 2019;11:53–69.30697064
   PubMed Web of Science ®Google Scholar
• HeX, XuC. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–669. doi:10.1038/s41422-020-0343-432467592
   PubMed Web of Science ®Google Scholar
• PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc323922437870
   PubMed Web of Science ®Google Scholar
• Xu-MonetteZY, ZhangM, LiJ, YoungKH. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response?Front Immunol. 2017;8:1597.29255458
   PubMed Web of Science ®Google Scholar
• SetordziP, ChangX, LiuZ, WuY, ZuoD. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. Eur J Pharmacol. 2021;895:173867. doi:10.1016/j.ejphar.2021.17386733460617
   PubMed Web of Science ®Google Scholar
• YuH, BoyleTA, ZhouC, RimmDL, HirschFR. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11(7):964–975. doi:10.1016/j.jtho.2016.04.01427117833
   PubMed Web of Science ®Google Scholar
• ChoueiriTK, FayAP, GrayKP, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–2184. doi:10.1093/annonc/mdu44525193987
   PubMed Web of Science ®Google Scholar
• NduomEK, WeiJ, YaghiNK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195–205. doi:10.1093/neuonc/nov17226323609
   PubMed Web of Science ®Google Scholar
• HinoR, KabashimaK, KatoY, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757–1766. doi:10.1002/cncr.2489920143437
   PubMed Web of Science ®Google Scholar
• HuangY, ZhangSD, McCruddenC, ChanKW, LinY, KwokHF. The prognostic significance of PD-L1 in bladder cancer. Oncol Rep. 2015;33(6):3075–3084. doi:10.3892/or.2015.393325963805
   PubMed Web of Science ®Google Scholar
• LiY, LiangL, DaiW, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016;15(1):55. doi:10.1186/s12943-016-0539-x27552968
   PubMed Web of Science ®Google Scholar
• BaptistaMZ, SarianLO, DerchainSF, PintoGA, VassalloJ. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2016;47(1):78–84. doi:10.1016/j.humpath.2015.09.00626541326
   PubMed Web of Science ®Google Scholar
• DillEA, GruAA, AtkinsKA, et al. PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am J Surg Pathol. 2017;41(3):334–342. doi:10.1097/PAS.000000000000078028195880
   PubMed Web of Science ®Google Scholar
• NodaM, MasudaT, ItoS, et al. Circulating PD-1 mRNA in peripheral blood is a potential biomarker for predicting survival of breast cancer patients. Ann Surg Oncol. 2020;27(10):4035–4043. doi:10.1245/s10434-020-08375-z32206951
   PubMed Web of Science ®Google Scholar
• DuH, YiZ, WangL, LiZ, NiuB, RenG. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. Int Immunopharmacol. 2020;78:106113. doi:10.1016/j.intimp.2019.10611331841754
   PubMed Web of Science ®Google Scholar
• MuenstS, SoysalSD, GaoF, ObermannEC, OertliD, GillandersWE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139(3):667–676. doi:10.1007/s10549-013-2581-323756627
   PubMed Web of Science ®Google Scholar
• VidulaN, YauC, RugoHS. Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. Breast Cancer Res Treat. 2021;187(2):387–395. doi:10.1007/s10549-021-06234-333913053
   PubMed Web of Science ®Google Scholar
• MatikasA, ZerdesI, LovrotJ, et al. PD-1 protein and gene expression as prognostic factors in early breast cancer. ESMO Open. 2020;5(6):e001032. doi:10.1136/esmoopen-2020-00103233172959
   PubMed Web of Science ®Google Scholar
• HuangW, RanR, ShaoB, LiH. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;178(1):17–33. doi:10.1007/s10549-019-05371-031359214
   PubMed Web of Science ®Google Scholar
• MuenstS, SchaerliAR, GaoF, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146(1):15–24. doi:10.1007/s10549-014-2988-524842267
   PubMed Web of Science ®Google Scholar
• MatikasA, ZerdesI, LovrotJ, et al. Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data. Clin Cancer Res. 2019;25(18):5717–5726. doi:10.1158/1078-0432.CCR-19-113131227501
   PubMed Web of Science ®Google Scholar
• KurozumiS, InoueK, MatsumotoH, et al. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Sci Rep. 2019;9(1):16662. doi:10.1038/s41598-019-52944-631723167
   PubMed Web of Science ®Google Scholar
• HouY, NittaH, WeiL, et al. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. Breast J. 2018;24(6):911–919. doi:10.1111/tbj.1311230230111
   PubMed Web of Science ®Google Scholar
• BarrettMT, LenkiewiczE, MalasiS, et al. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. Breast Cancer Res. 2018;20(1):71. doi:10.1186/s13058-018-1004-029996881
   PubMed Web of Science ®Google Scholar
• SabatierR, FinettiP, MamessierE, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6(7):5449–5464. doi:10.18632/oncotarget.321625669979
   PubMedGoogle Scholar
• AzourySC, StraughanDM, ShuklaV. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. 2015;15(6):452–462. doi:10.2174/15680096150615080514512026282545
   PubMed Web of Science ®Google Scholar
• NarayanP, WahbyS, GaoJJ, et al. FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res. 2020;26(10):2284–2289. doi:10.1158/1078-0432.CCR-19-354532001481
   PubMed Web of Science ®Google Scholar
• FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer. Available from:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple. Accessed July5, 2021.
   Google Scholar
• WHO Consultation on Obesity (‎1999: Geneva, Switzerland)‎ & World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. World Health Organization; 2000. Available from:https://apps.who.int/iris/handle/10665/42330. Accessed October30, 2021.
   Google Scholar
• EdgeSB, ComptonDR, FritzCC, GreeneAG, TrottiFA. AJCC Cancer Staging Handbook from the AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
   Google Scholar
• RakhaEA, Reis-FilhoJS, BaehnerF, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207. doi:10.1186/bcr260720804570
   PubMed Web of Science ®Google Scholar
• OnitiloAA, EngelJM, GreenleeRT, MukeshBN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4–13. doi:10.3121/cmr.2008.82519574486
   PubMedGoogle Scholar
• CianfroccaM, GoldsteinLJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606–616. doi:10.1634/theoncologist.9-6-60615561805
   PubMed Web of Science ®Google Scholar
• AyoubNM, YaghanRJ, AbdoNM, MatalkaII, Akhu-ZaheyaLM, Al-MohtasebAH. Impact of obesity on clinicopathologic characteristics and disease prognosis in pre- and postmenopausal breast cancer patients: a retrospective institutional study. J Obes. 2019;2019:3820759. doi:10.1155/2019/382075931019808
   PubMed Web of Science ®Google Scholar
• AlthammerS, TanTH, SpitzmullerA, et al. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. J Immunother Cancer. 2019;7(1):121. doi:10.1186/s40425-019-0589-x31060602
   PubMed Web of Science ®Google Scholar
• StarkA, StahlMS, KirchnerHL, KrumS, PrichardJ, EvansJ. Body mass index at the time of diagnosis and the risk of advanced stages and poorly differentiated cancers of the breast: findings from a case-series study. Int J Obes (Lond). 2010;34(9):1381–1386. doi:10.1038/ijo.2010.6920351736
   PubMed Web of Science ®Google Scholar
• Abdel-RazeqH, MansourA, JaddanD. Breast cancer care in Jordan. JCO Glob Oncol. 2020;6:260–268. doi:10.1200/JGO.19.0027932083950
   PubMedGoogle Scholar
• KythreotouA, SiddiqueA, MauriFA, BowerM, PinatoDJ. Pd-L1. J Clin Pathol. 2018;71(3):189–194. doi:10.1136/jclinpath-2017-20485329097600
   PubMed Web of Science ®Google Scholar
• JiaL, ZhangQ, ZhangR. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med. 2018;15(2):116–123. doi:10.20892/j.issn.2095-3941.2017.008629951336
   PubMed Web of Science ®Google Scholar
• LiS, ChenL, JiangJ. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: a systematic review and meta-analysis. Medicine. 2019;98(16):e15201. doi:10.1097/MD.000000000001520131008945
   PubMed Web of Science ®Google Scholar
• LouJ, ZhouY, HuangJ, QianX. Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma. Open Med (Wars). 2017;12:288–292. doi:10.1515/med-2017-004228894845
   PubMedGoogle Scholar
• EvangelouZ, Papoudou-BaiA, KarpathiouG, et al. PD-L1 expression and tumor-infiltrating lymphocytes in breast cancer: clinicopathological analysis in women younger than 40 years old. In Vivo. 2020;34(2):639–647. doi:10.21873/invivo.1181832111764
   PubMed Web of Science ®Google Scholar
• QinT, ZengYD, QinG, et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015;6(32):33972–33981. doi:10.18632/oncotarget.558326378017
   PubMed Web of Science ®Google Scholar
• AliHR, GlontSE, BlowsFM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26(7):1488–1493. doi:10.1093/annonc/mdv19225897014
   PubMed Web of Science ®Google Scholar
• KassardjianA, ShintakuPI, MoatamedNA. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. PLoS One. 2018;13(4):e0195958. doi:10.1371/journal.pone.019595829672601
   PubMed Web of Science ®Google Scholar
• ParvathareddySK, SirajAK, AhmedSO, et al. PD-L1 protein expression in middle eastern breast cancer predicts favorable outcome in triple-negative breast cancer. Cells. 2021;10:2. doi:10.3390/cells10020229
   Web of Science ®Google Scholar
• MansonQF, Ter HoeveND, BuergerH, MoelansCB, van DiestPJ. PD-1 and PD-L1 expression in male breast cancer in comparison with female breast cancer. Target Oncol. 2018;13(6):769–777. doi:10.1007/s11523-018-0610-130519815
   PubMed Web of Science ®Google Scholar
• MoriH, KuboM, YamaguchiR, et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget. 2017;8(9):15584–15592. doi:10.18632/oncotarget.1469828107186
   PubMedGoogle Scholar
• TawfikO, KimlerBF, KarnikT, ShehataP. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells. Hum Pathol. 2018;80:170–178. doi:10.1016/j.humpath.2018.06.00829936058
   PubMed Web of Science ®Google Scholar
• HouY, NittaH, WeiL, BanksPM, ParwaniAV, LiZ. Evaluation of immune reaction and PD-L1 expression using multiplex immunohistochemistry in HER2-positive breast cancer: the association with response to anti-HER2 neoadjuvant therapy. Clin Breast Cancer. 2018;18(2):e237–e244. doi:10.1016/j.clbc.2017.11.00129198959
   PubMed Web of Science ®Google Scholar
• ZhouT, XuD, TangB, et al. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis. Anticancer Drugs. 2018;29(9):904–910. doi:10.1097/CAD.000000000000068330085937
   PubMed Web of Science ®Google Scholar
• CriscitielloC, CuriglianoG. Immunotherapy of Breast Cancer. Prog Tumor Res. 2015;42:30–43.26377084
   PubMed Web of Science ®Google Scholar
• KimHS, DoSI, KimDH, AppleS. Clinicopathological and prognostic significance of programmed death Ligand 1 expression in Korean patients with triple-negative breast carcinoma. Anticancer Res. 2020;40(3):1487–1494. doi:10.21873/anticanres.1409332132048
   PubMed Web of Science ®Google Scholar
• TsangJY, AuWL, LoKY, et al. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Res Treat. 2017;162(1):19–30. doi:10.1007/s10549-016-4095-228058578
   PubMed Web of Science ®Google Scholar
• GuoY, YuP, LiuZ, et al. Prognostic and clinicopathological value of programmed death Ligand-1 in breast cancer: a meta-analysis. PLoS One. 2016;11(5):e0156323. doi:10.1371/journal.pone.015632327227453
   PubMed Web of Science ®Google Scholar
• AiErkenN, ShiHJ, ZhouY, et al. High PD-L1 expression is closely associated with tumor-infiltrating lymphocytes and leads to good clinical outcomes in Chinese triple negative breast cancer patients. Int J Biol Sci. 2017;13(9):1172–1179. doi:10.7150/ijbs.2086829104508
   PubMed Web of Science ®Google Scholar
• BrockhoffG, SeitzS, WeberF, et al. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. Oncotarget. 2018;9(5):6201–6212. doi:10.18632/oncotarget.2371729464065
   PubMedGoogle Scholar
• SoareGR, SoareCA. Immunotherapy for breast cancer: first FDA approved regimen. Discoveries (Craiova). 2019;7(1):e91. doi:10.15190/d.2019.432309609
   PubMedGoogle Scholar
• ShenX, ZhaoB. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529. doi:10.1136/bmj.k352930201790
   PubMed Web of Science ®Google Scholar
• LiuX, GuoCY, TouFF, et al. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: a systematic review and meta-analysis. Int J Cancer. 2020;147(1):116–127. doi:10.1002/ijc.3274431633798
   PubMed Web of Science ®Google Scholar